Antibody conjugates: From heterogeneous populations to defined reagents

Antibodies

Volumn 4, Issue 3, 2015, Pages 197-224

  Dennler, Patrick ^a   Fischer, Eliane ^a   Schibli, Roger ^a,b  

^a PAUL SCHERRER INSTITUTE   (Switzerland)

^b ETH ZURICH   (Switzerland)

Author keywords

Antibody conjugates; Bioconjugation; Chemical conjugation; Enzymatic conjugation; Immunoglobulin; Non covalent antibody conjugates

Indexed keywords

ANTIBODY CONJUGATE; BRENTUXIMAB VEDOTIN; CYSTEINE; ENZYME; FORMYLGLYCINE GENERATING ENZYME; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IODOACETAMIDE; LYSINE; MALEIMIDE; MONOCLONAL ANTIBODY; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; RADIOISOTOPE; SCAFFOLD PROTEIN; SELENOCYSTEINE; SORTASE; TRASTUZUMAB EMTANSINE; TYROSINE; UNCLASSIFIED DRUG;

BIOCONJUGATION; CARBOHYDRATE ANALYSIS; CHEMICAL CONJUGATION; CONJUGATION; COVALENT BOND; DRUG CONJUGATION; ENZYMATIC CONJUGATION; ENZYME MODIFICATION; HUMAN; IMMUNOREACTIVITY; METABOLIC ENGINEERING; NUCLEOTIDE BINDING SITE; PRIORITY JOURNAL; REVIEW;

EID: 85106466647     PISSN: 20734468     EISSN: None     Source Type: Journal    
DOI: 10.3390/antib4030197     Document Type: Review

References (182)

1. Köhler, G.; Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256, 495-497.
2. Vacchelli, E.; Aranda, F.; Eggermont, A.; Galon, J.; Sautes-Fridman, C.; Zitvogel, L.; Kroemer, G.; Galluzzi, L. Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology 2014, 3, e27048.
3. Reichert, J.M. Antibodies to watch in 2015. MAbs 2015, 7, 1-8.
4. Beck, A.; Reichert, J.M. Antibody-drug conjugates: present and future. MAbs 2014, 6, 15-17.
5. Papachristos, A.; Pippa, N.; Demetzos, C.; Sivolapenko, G. Antibody-drug conjugates: A minireview. The synopsis of two approved medicines. Drug Deliv. 2015, 1-5.
6. Kraeber-Bodere, F.; Bodet-Milin, C.; Rousseau, C.; Eugene, T.; Pallardy, A.; Frampas, E.; Carlier, T.; Ferrer, L.; Gaschet, J.; Davodeau, F.; et al. Radioimmunoconjugates for the treatment of cancer. Semin. Oncol. 2014, 41, 613-622.
7. Sapra, P.; Hooper, A.; O'Donnell, C.; Gerber, H.-P. Investigational antibody drug conjugates for solid tumors. Expert Opin. Investig. Drugs 2011, 20, 1131-1180.
8. Flygare, J.; Pillow, T.; Aristoff, P. Antibody-drug conjugates for the treatment of cancer. Chem. Biol. Drug Des. 2013, 81, 113-121.
9. Panowski, S.; Bhakta, S.; Raab, H.; Polakis, P.; Junutula, J.R. Site-specific antibody drug conjugates for cancer therapy. MAbs 2013, 6, 34-45.
10. Stephanopoulos, N.; Francis, M.B. Choosing an effective protein bioconjugation strategy. Nat. Chem. Biol. 2011, 7, 876-884.
11. Hamblett, K.J.; Senter, P.D.; Chace, D.F.; Sun, M.M.; Lenox, J.; Cerveny, C.G.; Kissler, K.M.; Bernhardt, S.X.; Kopcha, A.K.; Zabinski, R.F.; et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer. Res. 2004, 10, 7063-7070.
12. Boswell, C.A.; Mundo, E.E.; Zhang, C.; Bumbaca, D.; Valle, N.R.; Kozak, K.R.; Fourie, A.; Chuh, J.; Koppada, N.; Saad, O.; et al. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug. Chem. 2011, 22, 1994-2004.
13. Jackson, D.; Atkinson, J.; Guevara, C.I.; Zhang, C.; Kery, V.; Moon, S.-J.J.; Virata, C.; Yang, P.; Lowe, C.; Pinkstaff, J.; et al. In vitro and in vivo evaluation of cysteine and site-specific conjugated herceptin antibody-drug conjugates. PloS One 2014, 9, e83865:14
14. Behrens, C.R.; Liu, B. Methods for site-specific drug conjugation to antibodies. mAbs 2013, 6, 46-53.
15. Kline, T.; Steiner, A.R.; Penta, K.; Sato, A.K.; Hallam, T.J.; Yin, G. Methods to make homogenous antibody drug conjugates. Pharm. Res. 2014, doi: 10.1007/s11095-014-1596-8.
16. Agarwal, P.; Bertozzi, C.R. Site-specific antibody-drug conjugates: The nexus of bioorthogonal chemistry, protein engineering, and drug development. Bioconjug. Chem. 2015, 26, 176-192.
17. Sochaj, A.M.; Swiderska, K.W.; Otlewski, J. Current methods for the synthesis of homogeneous antibody-drug conjugates. Biotechnol. Adv. 2015, doi: 10.1016/j.biotechadv.2015.05.001.
18. Zhou, Q.; Kim, J. Advances in the development of site-specific antibody-drug conjugation. Anticancer Agents Med. Chem. 2015, 15, 828-836.
19. McCombs, J.R.; Owen, S.C. Antibody drug conjugates: Design and selection of linker, payload and conjugation chemistry. AAPS J. 2015, 17, 339-351.
20. Glazer, A.N. Specific chemical modification of proteins. Annu. Rev. Biochem. 1970, 39, 101-130.
21. Ghose, T.I.; Blair, A.H.; Kulkarni, P.N. Preparation of antibody-linked cytotoxic agents. Methods Enzymol. 1983, 93, 280-333.
22. Hermanson, G.T. Bioconjugate Techniques; Academic Press: New York, NY, USA, 2008; pp. 1041-1132.
23. Gauthier, M.A.; Klok, H.-A. Peptide/protein-polymer conjugates: Synthetic strategies and design concepts. Chem. Commun. (Cambridge, U. K.) 2008, 21, 2591-2611.
24. Francis, M.B. New methods for protein bioconjugation. In Chemical Biology; Wiley-VCH Verlag GmbH: Weinheim, Germany, 2008; pp. 593-634.
25. Sletten, E.M.; Bertozzi, C.R. Bioorthogonal chemistry: Fishing for selectivity in a sea of functionality. Angew. Chem. Int. Ed. Engl. 2009, 48, 6974-6998.
26. Mueller, B.M.; Wrasidlo, W.A.; Reisfeld, R.A. Determination of the number of e-amino groups available for conjugation of effector molecules to monoclonal antibodies. Hybridoma 1988, 7, 453-456.
27. Widdison, W.C.; Wilhelm, S.D.; Cavanagh, E.E.; Whiteman, K.R.; Leece, B.A.; Kovtun, Y.; Goldmacher, V.S.; Xie, H.; Steeves, R.M.; Lutz, R.J.; et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J. Med. Chem. 2006, 49, 4392-4408.
28. Wakankar, A.A.; Feeney, M.B.; Rivera, J.; Chen, Y.; Kim, M.; Sharma, V.K.; Wang, Y.J. Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: Changes due to modification and conjugation processes. Bioconjug. Chem. 2010, 21, 1588-1595.
29. Siegel, M.M.; Tabei, K.; Kunz, A.; Hollander, I.J.; Hamann, R.R.; Bell, D.H.; Berkenkamp, S.; Hillenkamp, F. Calicheamicin derivatives conjugated to monoclonal antibodies: determination of loading values and distributions by infrared and UV matrix-assisted laser desorption/ionization mass spectrometry and electrospray ionization mass spectrometry. Anal. Chem. 1997, 69, 2716-2726.
30. Adamczyk, M.; Gebler, J.; Shreder, K.; Wu, J. Region-selective labeling of antibodies as determined by electrospray ionization-mass spectrometry (ESI-MS). Bioconjug. Chem. 2000, 11, 557-563.
31. Wang, L.; Amphlett, G.; Blattler, W.A.; Lambert, J.M.; Zhang, W. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci. 2005, 14, 2436-2446.
32. Hamann, P.R.; Hinman, L.M.; Hollander, I.; Beyer, C.F.; Lindh, D.; Holcomb, R.; Hallett, W.; Tsou, H.R.; Upeslacis, J.; Shochat, D.; et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem. 2002, 13, 47-58.
33. Feng, Y.; Zhu, Z.; Chen, W.; Prabakaran, P.; Lin, K.; Dimitrov, D. Conjugates of small molecule drugs with antibodies and other proteins. Biomedicines 2014, 2, 1-13.
34. Hess, C.; Venetz, D.; Neri, D. Emerging classes of armed antibody therapeutics against cancer. Med. Chem. Commun. 2014, 5, 408-431.
35. Kalkhof, S.; Sinz, A. Chances and pitfalls of chemical cross-linking with amine-reactive N-hydroxysuccinimide esters. Anal. Bioanal. Chem. 2008, 392, 305-312.
36. Madler, S.; Bich, C.; Touboul, D.; Zenobi, R. Chemical cross-linking with NHS esters: A systematic study on amino acid reactivities. J. Mass Spectrom. 2009, 44, 694-706.
37. Chih, H.W.; Gikanga, B.; Yang, Y.; Zhang, B. Identification of amino acid residues responsible for the release of free drug from an antibody-drug conjugate utilizing lysine-succinimidyl ester chemistry. J. Pharm. Sci. 2011, 100, 2518-2525.
38. Goto, Y.; Hamaguchi, K. The role of the intrachain disulfide bond in the conformation and stability of the constant fragment of the immunoglobulin light chain. J. Biochem. 1979, 86, 1433-1441.
39. Proba, K.; Honegger, A.; Pluckthun, A. A natural antibody missing a cysteine in VH: consequences for thermodynamic stability and folding. J. Mol. Biol. 1997, 265, 161-172.
40. Thies, M.J.; Talamo, F.; Mayer, M.; Bell, S.; Ruoppolo, M.; Marino, G.; Buchner, J. Folding and oxidation of the antibody domain CH3. J. Mol. Biol. 2002, 319, 1267-1277.
41. McAuley, A.; Jacob, J.; Kolvenbach, C.G.; Westland, K.; Lee, H.J.; Brych, S.R.; Rehder, D.; Kleemann, G.R.; Brems, D.N.; Matsumura, M. Contributions of a disulfide bond to the structure, stability, and dimerization of human IgG1 antibody CH3 domain. Protein Sci. 2008, 17, 95-106.
42. Liu, H.; Chumsae, C.; Gaza-Bulseco, G.; Hurkmans, K.; Radziejewski, C.H. Ranking the susceptibility of disulfide bonds in human IgG1 antibodies by reduction, differential alkylation, and LC-MS analysis. Anal. Chem. 2010, 82, 5219-5226.
43. Sun, M.M.; Beam, K.S.; Cerveny, C.G.; Hamblett, K.J.; Blackmore, R.S.; Torgov, M.Y.; Handley, F.G.; Ihle, N.C.; Senter, P.D.; Alley, S.C. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug. Chem. 2005, 16, 1282-1290.
44. McDonagh, C.F.; Turcott, E.; Westendorf, L.; Webster, J.B.; Alley, S.C.; Kim, K.; Andreyka, J.; Stone, I.; Hamblett, K.J.; Francisco, J.A.; et al. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng. Des. Sel. 2006, 19, 299-307.
45. Doronina, S.O.; Toki, B.E.; Torgov, M.Y.; Mendelsohn, B.A.; Cerveny, C.G.; Chace, D.F.; DeBlanc, R.L.; Gearing, R.P.; Bovee, T.D.; Siegall, C.B.; et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 2003, 21, 778-784.
46. Cal, P.M.; Bernardes, G.J.; Gois, P.M. Cysteine-selective reactions for antibody conjugation. Angew. Chem. Int. Ed. Engl. 2014, 53, 10585-10587.
47. Patterson, J.T.; Asano, S.; Li, X.; Rader, C.; Barbas, C.F. Improving the serum stability of sitespecific antibody conjugates with sulfone linkers. Bioconjug. Chem. 2014, 25, 1402-1407.
48. Badescu, G.; Bryant, P.; Bird, M.; Henseleit, K.; Swierkosz, J.; Parekh, V.; Tommasi, R.; Pawlisz, E.; Jurlewicz, K.; Farys, M.; et al. Bridging disulfides for stable and defined antibody drug conjugates. Bioconjug. Chem. 2014, 25, 1124-1136.
49. Bryant, P.; Pabst, M.; Badescu, G.; Bird, M.; McDowell, W.; Jamieson, E.; Swierkosz, J.; Jurlewicz, K.; Tommasi, R.; Henseleit, K.; et al. In vitro and In vivo evaluation of cysteine rebridged trastuzumab-MMAE antibody drug conjugates with defined drug-to-antibody ratios. Mol. Pharm. 2015, 12, 1872-1879.
50. Schumacher, F.F.; Nunes, J.P.; Maruani, A.; Chudasama, V.; Smith, M.E.; Chester, K.A.; Baker, J.R.; Caddick, S. Next generation maleimides enable the controlled assembly of antibody-drug conjugates via native disulfide bond bridging. Org. Biomol. Chem. 2014, 12, 7261-7269.
51. Nunes, J.P.; Morais, M.; Vassileva, V.; Robinson, E.; Rajkumar, V.S.; Smith, M.E.; Pedley, R.B.; Caddick, S.; Baker, J.R.; Chudasama, V. Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody-drug conjugate (ADC). Chem. Commun. (Camb.) 2015, 51, 10624-10627.
52. Maruani, A.; Smith, M.E.; Miranda, E.; Chester, K.A.; Chudasama, V.; Caddick, S. A plug-andplay approach to antibody-based therapeutics via a chemoselective dual click strategy. Nat. Commun. 2015, 6, 6645.
53. Lyon, R.P.; Setter, J.R.; Bovee, T.D.; Doronina, S.O.; Hunter, J.H.; Anderson, M.E.; Balasubramanian, C.L.; Duniho, S.M.; Leiske, C.I.; Li, F.; et al. Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates. Nat. Biotechnol. 2014, 32, 1059-1062.
54. Tumey, L.N.; Charati, M.; He, T.; Sousa, E.; Ma, D.; Han, X.; Clark, T.; Casavant, J.; Loganzo, F.; Barletta, F.; et al. Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy. Bioconjug. Chem. 2014, 25, 1871-1880.
55. Stimmel, J.B.; Merrill, B.M.; Kuyper, L.F.; Moxham, C.P.; Hutchins, J.T.; Fling, M.E.; Kull, F.C., Jr. Site-specific conjugation on serine right-arrow cysteine variant monoclonal antibodies. J. Biol. Chem. 2000, 275, 30445-30450.
56. Bhakta, S.; Raab, H.; Junutula, J. Engineering THIOMABs for site-specific conjugation of thiolreactive linkers. In Antibody-Drug Conjugates; Ducry, L., Ed.; Humana Press: New York, NJ, USA, 2013; Volume 1045, pp. 189-203.
57. Junutula, J.R.; Raab, H.; Clark, S.; Bhakta, S.; Leipold, D.D.; Weir, S.; Chen, Y.; Simpson, M.; Tsai, S.P.; Dennis, M.S.; et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 2008, 26, 925-932.
58. Shen, B.Q.; Xu, K.; Liu, L.; Raab, H.; Bhakta, S.; Kenrick, M.; Parsons-Reponte, K.L.; Tien, J.; Yu, S.F.; Mai, E.; et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat. Biotechnol. 2012, 30, 184-189.
59. Caron, P.C.; Laird, W.; Co, M.S.; Avdalovic, N.M.; Queen, C.; Scheinberg, D.A. Engineered humanized dimeric forms of IgG are more effective antibodies. J. Exp. Med. 1992, 176, 1191-1195.
60. Shopes, B. A genetically engineered human IgG with limited flexibility fully initiates cytolysis via complement. Mol. Immunol. 1993, 30, 603-609.
61. Baldwin, A.D.; Kiick, K.L. Tunable degradation of maleimide-thiol adducts in reducing environments. Bioconjug. Chem. 2011, 22, 1946-1953.
62. Alley, S.C.; Benjamin, D.R.; Jeffrey, S.C.; Okeley, N.M.; Meyer, D.L.; Sanderson, R.J.; Senter, P.D. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug. Chem. 2008, 19, 759-765.
63. Johansson, L.; Chen, C.; Thorell, J.-O.; Fredriksson, A.; Stone-Elander, S.; Gafvelin, G.; Arnér, E. Exploiting the 21st amino acid-purifying and labeling proteins by selenolate targeting. Nat. Methods 2004, 1, 61-67.
64. Hofer, T.; Skeffington, L.R.; Chapman, C.M.; Rader, C. Molecularly defined antibody conjugation through a selenocysteine interface. Biochemistry 2009, 48, 12047-12057.
65. Hofer, T.; Thomas, J.D.; Burke, T.R., Jr.; Rader, C. An engineered selenocysteine defines a unique class of antibody derivatives. Proc. Natl. Acad. Sci. USA 2008, 105, 12451-12456.
66. Li, X.; Yang, J.; Rader, C. Antibody conjugation via one and two C-terminal selenocysteines. Methods (San Diego, Calif.) 2014, 65, 133-138.
67. Ban, H.; Gavrilyuk, J.; Barbas, C.F., 3rd. Tyrosine bioconjugation through aqueous ene-type reactions: a click-like reaction for tyrosine. J. Am. Chem. Soc. 2010, 132, 1523-1525.
68. Ban, H.; Nagano, M.; Gavrilyuk, J.; Hakamata, W.; Inokuma, T.; Barbas, C. Facile and stabile linkages through tyrosine: Bioconjugation strategies with the tyrosine-click reaction. Bioconjug. Chem. 2013, 24, 520-532.
69. Gavrilyuk, J.; Ban, H.; Nagano, M.; Hakamata, W.; Barbas, C. Formylbenzene diazonium hexafluorophosphate reagent for tyrosine-selective modification of proteins and the introduction of a bioorthogonal aldehyde. Bioconjug. Chem. 2012, 23, 2321-2328.
70. Gavrilyuk, J.; Ban, H.; Uehara, H.; Sirk, S.J.; Saye-Francisco, K.; Cuevas, A.; Zablowsky, E.; Oza, A.; Seaman, M.S.; Burton, D.R.; et al. Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG. J. Virol. 2013, 87, 4985-4993.
71. Hallam, T.J.; Smider, V.V. Unnatural amino acids in novel antibody conjugates. Future Med. Chem. 2014, 6, 1309-1324.
72. Wang, Q.; Parrish, A.R.; Wang, L. Expanding the genetic code for biological studies. Chem. Biol. 2009, 16, 323-336.
73. Kim, C.H.; Axup, J.Y.; Schultz, P.G. Protein conjugation with genetically encoded unnatural amino acids. Curr. Opin. Chem. Biol. 2013, 17, 412-419.
74. Axup, J.; Bajjuri, K.; Ritland, M.; Hutchins, B.; Kim, C.; Kazane, S.; Halder, R.; Forsyth, J.; Santidrian, A.; Stafin, K.; et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc. Natl. Acad. Sci. USA 2012, 109, 16101-16106.
75. Xiao, H.; Chatterjee, A.; Choi, S.-H.; Bajjuri, K.M.; Sinha, S.C.; Schultz, P.G. Genetic incorporation of multiple unnatural amino acids into proteins in mammalian cells. Angew. Chem. Int. Ed. Engl. 2013, 52, 14080-14083.
76. Abaturov, L.V.; Nezlin, R.S.; Vengerova, T.I.; Varshavsky, J.M. Conformational studies of immunoglobulin G and its subunits by the methods of hydrogen-deuterium exchange and infrared spectroscopy. Biochim. Biophys. Acta 1969, 194, 386-396.
77. Calmettes, P.; Cser, L.; Rajnavolgyi, E. Temperature and pH dependence of immunoglobulin G conformation. Arch. Biochem. Biophys. 1991, 291, 277-283.
78. Ejima, D.; Tsumoto, K.; Fukada, H.; Yumioka, R.; Nagase, K.; Arakawa, T.; Philo, J.S. Effects of acid exposure on the conformation, stability, and aggregation of monoclonal antibodies. Proteins 2007, 66, 954-962.
79. Yin, G.; Garces, E.D.; Yang, J.; Zhang, J.; Tran, C.; Steiner, A.R.; Roos, C.; Bajad, S.; Hudak, S.; Penta, K.; et al. Aglycosylated antibodies and antibody fragments produced in a scalable in vitro transcription-translation system. MAbs 2012, 4, 217-225.
80. Ozawa, K.; Loscha, K.V.; Kuppan, K.V.; Loh, C.T.; Dixon, N.E.; Otting, G. High-yield cell-free protein synthesis for site-specific incorporation of unnatural amino acids at two sites. Biochem. Biophys. Res. Commun. 2012, 418, 652-656.
81. Caschera, F.; Noireaux, V. Synthesis of 2.3 mg/ml of protein with an all Escherichia coli cell-free transcription-translation system. Biochimie 2014, 99, 162-168.
82. Hong, S.H.; Kwon, Y.-C.C.; Jewett, M.C. Non-standard amino acid incorporation into proteins using Escherichia coli cell-free protein synthesis. Front. Chem. 2014, 2, 34.
83. Zimmerman, E.S.; Heibeck, T.H.; Gill, A.; Li, X.; Murray, C.J.; Madlansacay, M.R.; Tran, C.; Uter, N.T.; Yin, G.; Rivers, P.J.; et al. Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system. Bioconjug. Chem. 2014, 25, 351-361.
84. O'Shannessy, D.J.; Dobersen, M.J.; Quarles, R.H. A novel procedure for labeling immunoglobulins by conjugation to oligosaccharide moieties. Immunol. Lett. 1984, 8, 273-277.
85. Kralovec, J.; Spencer, G.; Blair, A.H.; Mammen, M.; Singh, M.; Ghose, T. Synthesis of methotrexate-antibody conjugates by regiospecific coupling and assessment of drug and antitumor activities. J. Med. Chem. 1989, 32, 2426-2431.
86. Laguzza, B.C.; Nichols, C.L.; Briggs, S.L.; Cullinan, G.J.; Johnson, D.A.; Starling, J.J.; Baker, A.L.; Bumol, T.F.; Corvalan, J.R. New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: Design, preparation, and representative in vivo activity. J. Med. Chem. 1989, 32, 548-555.
87. Johnson, D.A.; Baker, A.L.; Laguzza, B.C.; Fix, D.V.; Gutowski, M.C. Antitumor activity of L/1C2-4-desacetylvinblastine-3-carboxhydrazide immunoconjugate in xenografts. Cancer Res. 1990, 50, 1790-1794.
88. Zuberbühler, K.; Casi, G.; Bernardes, G.J.; Neri, D. Fucose-specific conjugation of hydrazide derivatives to a vascular-targeting monoclonal antibody in IgG format. Chem. Commun. (Camb.) 2012, 48, 7100-7102.
89. Ranadive, G.N.; Rosenzweig, H.S.; Epperly, M.W.; Seskey, T.; Bloomer, W.D. A new method of technetium-99m labeling of monoclonal antibodies through sugar residues. A study with TAG-72 specific CC-49 antibody. Nucl. Med. Biol. 1993, 20, 719-726.
90. Rodwell, J.D.; Alvarez, V.L.; Lee, C.; Lopes, A.D.; Goers, J.W.; King, H.D.; Powsner, H.J.; McKearn, T.J. Site-specific covalent modification of monoclonal antibodies: In vitro and in vivo evaluations. Proc. Natl. Acad. Sci. USA 1986, 83, 2632-2636.
91. Husain, M.; Bieniarz, C. Fc site-specific labeling of immunoglobulins with calf intestinal alkaline phosphatase. Bioconjug. Chem. 1994, 5, 482-490.
92. Liang, J.F.; Li, Y.T.; Connell, M.E.; Yang, V.C. Synthesis and characterization of positively charged tPA as a prodrug using heparin/protamine-based drug delivery system. AAPS PharmSci 2000, 2, E7.
93. Liang, J.F.; Park, Y.J.; Song, H.; Li, Y.T.; Yang, V.C. ATTEMPTS: a heparin/protamine-based prodrug approach for delivery of thrombolytic drugs. J. Control. Release 2001, 72, 145-156.
94. Park, Y.-J.; Liang, J.-F.; Song, H.; Li, Y.T.; Naik, S.; Yang, V.C. ATTEMPTS: A heparin/protamine-based triggered release system for the delivery of enzyme drugs without associated side-effects. Adv. Drug Deliv. Rev. 2003, 55, 251-265.
95. Raju, T.S.; Jordan, R.E. Galactosylation variations in marketed therapeutic antibodies. MAbs 2012, 4, 385-391.
96. Zauner, G.; Selman, M.H.; Bondt, A.; Rombouts, Y.; Blank, D.; Deelder, A.M.; Wuhrer, M. Glycoproteomic analysis of antibodies. Mol. Cell. Proteomics 2013, 12, 856-865.
97. Jefferis, R. Glycosylation of recombinant antibody therapeutics. Biotechnol. Prog. 2005, 21, 11-16.
98. Abraham, R.; Moller, D.; Gabel, D.; Senter, P.; Hellstrom, I.; Hellstrom, K.E. The influence of periodate oxidation on monoclonal antibody avidity and immunoreactivity. J. Immunol. Methods 1991, 144, 77-86.
99. Wolfe, C.A.; Hage, D.S. Studies on the rate and control of antibody oxidation by periodate. Anal. Biochem. 1995, 231, 123-130.
100. Hage, D.S.; Wolfe, C.A.; Oates, M.R. Development of a kinetic model to describe the effective rate of antibody oxidation by periodate. Bioconjug. Chem. 1997, 8, 914-920.
101. Solomon, B.; Koppel, R.; Schwartz, F.; Fleminger, G. Enzymic oxidation of monoclonal antibodies by soluble and immobilized bifunctional enzyme complexes. J. Chromatogr. A 1990, 510, 321-329.
102. Zhou, Q.; Stefano, J.E.; Manning, C.; Kyazike, J.; Chen, B.; Gianolio, D.A.; Park, A.; Busch, M.; Bird, J.; Zheng, X.; et al. Site-specific antibody-drug conjugation through glycoengineering. Bioconjug. Chem. 2014, 25, 510-520.
103. Li, X.; Fang, T.; Boons, G.J. Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions. Angew. Chem. Int. Ed. Engl. 2014, 53, 7179-7182.
104. Boeggeman, E.; Ramakrishnan, B.; Kilgore, C.; Khidekel, N.; Hsieh-Wilson, L.C.; Simpson, J.T.; Qasba, P.K. Direct identification of nonreducing GlcNAc residues on N-glycans of glycoproteins using a novel chemoenzymatic method. Bioconjug. Chem. 2007, 18, 806-814.
105. Boeggeman, E.; Ramakrishnan, B.; Pasek, M.; Manzoni, M.; Puri, A.; Loomis, K.H.; Waybright, T.J.; Qasba, P.K. Site specific conjugation of fluoroprobes to the remodeled Fc N-glycans of monoclonal antibodies using mutant glycosyltransferases: Application for cell surface antigen detection. Bioconjug. Chem. 2009, 20, 1228-1236.
106. Zeglis, B.M.; Davis, C.B.; Aggeler, R.; Kang, H.-C.; Chen, A.; Agnew, B.; Lewis, J.S. An enzymemediated methodology for the site-specific radiolabeling of antibodies based on catalyst-free click chemistry. Bioconjug. Chem. 2013, 42, 1057-1067.
107. Zeglis, B.M.; Davis, C.B.; Abdel-Atti, D.; Carlin, S.D.; Chen, A.; Aggeler, R.; Agnew, B.J.; Lewis, J.S. Chemoenzymatic strategy for the synthesis of site-specifically labeled immunoconjugates for multimodal PET and optical imaging. Bioconjug. Chem. 2014, 25, 2123-2128.
108. Zhu, Z.; Ramakrishnan, B.; Li, J.; Wang, Y.; Feng, Y.; Prabakaran, P.; Colantonio, S.; Dyba, M.A.; Qasba, P.K.; Dimitrov, D.S. Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar. MAbs 2014, 6, 1190-1200.
109. van Geel, R.; Wijdeven, M.A.; Heesbeen, R.; Verkade, J.M.; Wasiel, A.A.; van Berkel, S.S.; van Delft, F.L. Chemoenzymatic conjugation of toxic payloads to the globally conserved N-glycan of native mAbs provides homogeneous and highly efficacious antibody-drug conjugates. Bioconjug. Chem. 2015, doi: 10.1021/acs.bioconjchem.5b00224.
110. Okeley, N.M.; Toki, B.E.; Zhang, X.; Jeffrey, S.C.; Burke, P.J.; Alley, S.C.; Senter, P.D. Metabolic engineering of monoclonal antibody carbohydrates for antibody-drug conjugation. Bioconjug. Chem. 2013, 24, 1650-1655.
111. Vidarsson, G.; Dekkers, G.; Rispens, T. IgG subclasses and allotypes: From structure to effector functions. Front. Immunol. 2014, 5, 520.
112. Arnold, J.N.; Wormald, M.R.; Sim, R.B.; Rudd, P.M.; Dwek, R.A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 2007, 25, 21-50.
113. Bondt, A.; Rombouts, Y.; Selman, M.H.; Hensbergen, P.J.; Reiding, K.R.; Hazes, J.M.; Dolhain, R.J.; Wuhrer, M. Immunoglobulin G (IgG) Fab glycosylation analysis using a new mass spectrometric high-throughput profiling method reveals pregnancy-associated changes. Mol. Cell. Proteomics 2014, 13, 3029-3039.
114. Scheck, R.A.; Francis, M.B. Regioselective labeling of antibodies through N-terminal transamination. ACS Chem. Biol. 2007, 2, 247-251.
115. Witus, L.S.; Netirojjanakul, C.; Palla, K.S.; Muehl, E.M.; Weng, C.H.; Iavarone, A.T.; Francis, M.B. Site-specific protein transamination using N-methylpyridinium-4-carboxaldehyde. J. Am. Chem. Soc. 2013, 135, 17223-17229.
116. Sack, J.T.; Stephanopoulos, N.; Austin, D.C.; Francis, M.B.; Trimmer, J.S. Antibody-guided photoablation of voltage-gated potassium currents. J. Gen. Physiol. 2013, 142, 315-324.
117. Rabuka, D. Chemoenzymatic methods for site-specific protein modification. Curr. Opin. Chem. Biol. 2010, 14, 790-796.
118. Rashidian, M.; Dozier, J.; Distefano, M. Enzymatic labeling of proteins: techniques and approaches. Bioconjug. Chem. 2013, 24, 1277-1294.
119. Carrico, I.S.; Carlson, B.L.; Bertozzi, C.R. Introducing genetically encoded aldehydes into proteins. Nat. Chem. Biol. 2007, 3, 321-322.
120. Wu, P.; Shui, W.; Carlson, B.L.; Hu, N.; Rabuka, D.; Lee, J.; Bertozzi, C.R. Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag. Proc. Natl. Acad. Sci. USA 2009, 106, 3000-3005.
121. Rabuka, D.; Rush, J.; deHart, G.; Wu, P.; Bertozzi, C. Site-specific chemical protein conjugation using genetically encoded aldehyde tags. Nat. Protoc. 2012, 7, 1052-1119.
122. Hudak, J.; Barfield, R.; de Hart, G.; Grob, P.; Nogales, E.; Bertozzi, C.; Rabuka, D. Synthesis of heterobifunctional protein fusions using copper-free click chemistry and the aldehyde tag. Angew. Chem. Int. Ed. Engl. 2012, 51, 4161-4166.
123. Agarwal, P.; van der Weijden, J.; Sletten, E.M.; Rabuka, D.; Bertozzi, C.R. A Pictet-Spengler ligation for protein chemical modification. Proc. Natl. Acad. Sci. USA 2013, 110, 46-51.
124. Parthasarathy, R.; Subramanian, S.; Boder, E.T. Sortase A as a novel molecular "stapler" for sequence-specific protein conjugation. Bioconjug. Chem. 2007, 18, 469-476.
125. Popp, M.W.; Antos, J.M.; Grotenbreg, G.M.; Spooner, E.; Ploegh, H.L. Sortagging: A versatile method for protein labeling. Nat. Chem. Biol. 2007, 3, 707-708.
126. Ritzefeld, M. Sortagging: A robust and efficient chemoenzymatic ligation strategy. Chemistry 2014, 20, 8516-8529.
127. Levary, D.A.; Parthasarathy, R.; Boder, E.T.; Ackerman, M.E. Protein-protein fusion catalyzed by sortase A. PLoS One 2011, 6, e18342:6.
128. Swee, L.K.; Guimaraes, C.P.; Sehrawat, S.; Spooner, E.; Barrasa, M.I.; Ploegh, H.L. Sortasemediated modification of aDEC205 affords optimization of antigen presentation and immunization against a set of viral epitopes. Proc. Natl. Acad. Sci. USA 2013, 110, 1428-1433.
129. Wagner, K.; Kwakkenbos, M.J.; Claassen, Y.B.; Maijoor, K.; Böhne, M.; van der Sluijs, K.F.; Witte, M.D.; van Zoelen, D.J.; Cornelissen, L.A.; Beaumont, T.; et al. Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity. Proc. Natl. Acad. Sci. USA 2014, 111, 16820-16825.
130. Bellucci, J.J.; Bhattacharyya, J.; Chilkoti, A. A noncanonical function of sortase enables sitespecific conjugation of small molecules to lysine residues in proteins. Angew. Chem. Int. Ed. Engl. 2014, 54, 441-445.
131. Ando, H.; Adachi, M.; Umeda, K.; Matsuura, A.; Nonaka, M.; Uchio, R.; Tanaka, H.; Motoki, M. Purification and characteristics of a novel transglutaminase derived from microorganisms. Agric. Biol. Chem. 1989, 53, 2613-2617.
132. Zhu, Y.; Tramper, J. Novel applications for microbial transglutaminase beyond food processing. Trends Biotechnol. 2008, 26, 559-565.
133. Strop, P. Versatility of microbial transglutaminase. Bioconjug. Chem. 2014, 25, 855-862.
134. Josten, A.; Haalck, L.; Spener, F.; Meusel, M. Use of microbial transglutaminase for the enzymatic biotinylation of antibodies. J. Immunol. Methods 2000, 240, 47-54.
135. Mindt, T.L.; Jungi, V.; Wyss, S.; Friedli, A.; Pla, G.; Novak-Hofer, I.; Grünberg, J.; Schibli, R. Modification of different IgG1 antibodies via glutamine and lysine using bacterial and human tissue transglutaminase. Bioconjug. Chem. 2008, 19, 271-278.
136. Jeger, S.; Zimmermann, K.; Blanc, A.; Gruenberg, J.; Honer, M.; Hunziker, P.; Struthers, H.; Schibli, R. Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. Angew. Chem. Int. Ed. Engl. 2010, 49, 9995-9997.
137. Dennler, P.; Chiotellis, A.; Fischer, E.; Bregeon, D.; Belmant, C.; Gauthier, L.; Lhospice, F.; Romagne, F.; Schibli, R. Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates. Bioconjug. Chem. 2014, 25, 569-578.
138. Lhospice, F.; Brégeon, D.; Belmant, C.; Dennler, P.; Chiotellis, A.; Fischer, E.; Gauthier, L.; Boëdec, A.; Rispaud, H.; Savard-Chambard, S.; et al. Site-specific conjugation of monomethyl auristatin E to anti-CD30 antibodies improves their pharmacokinetics and therapeutic index in rodent models. Mol. Pharm. 2015, 12, 1863-1871.
139. Strop, P.; Liu, S.-H.; Dorywalska, M.; Delaria, K.; Dushin, R.; Tran, T.-T.; Ho, W.-H.; Farias, S.; Casas, M.; Abdiche, Y.; et al. Location matters: Site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem. Biol. 2013, 20, 161-167.
140. Dorywalska, M.; Strop, P.; Melton-Witt, J.A.; Hasa-Moreno, A.; Farias, S.E.; Galindo Casas, M.; Delaria, K.; Lui, V.; Poulsen, K.; Loo, C.; et al. Effect of attachment site on stability of cleavable antibody drug conjugates. Bioconjug. Chem. 2015, 26, 650-659.
141. Nilsson, B.; Moks, T.; Jansson, B.; Abrahmsen, L.; Elmblad, A.; Holmgren, E.; Henrichson, C.; Jones, T.A.; Uhlen, M. A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng. 1987, 1, 107-113.
142. Forsgren, A.; Sjöquist, J. Protein A from S. Aureus. J. Immunol. 1966, 97, 822-827.
143. Iangone, J.J. Protein A of Staphylococcus aureus and related immunoglobulin receptors produced by Streptococci and Pneumonococci. In Advances in Immunology; Frank, J.D., Henry, G.K., Eds.; Academic Press: New York, NJ, USA, 1982; Volume 32, pp. 157-252.
144. Kurata, N.; Shishido, T.; Muraoka, M.; Tanaka, T.; Ogino, C.; Fukuda, H.; Kondo, A. Specific protein delivery to target cells by antibody-displaying bionanocapsules. J. Biochem. 2008, 144, 701-707.
145. Iijima, M.; Matsuzaki, T.; Yoshimoto, N.; Niimi, T.; Tanizawa, K.; Kuroda, S.I. Fluorophorelabeled nanocapsules displaying IgG Fc-binding domains for the simultaneous detection of multiple antigens. Biomaterials 2011, 32, 9011-9031.
146. Iijima, M.; Kadoya, H.; Hatahira, S.; Hiramatsu, S.; Jung, G.; Martin, A.; Quinn, J.; Jung, J.; Jeong, S.-Y.; Choi, E.; et al. Nanocapsules incorporating IgG Fc-binding domain derived from Staphylococcus aureus protein A for displaying IgGs on immunosensor chips. Biomaterials 2011, 32, 1455-1519.
147. Iijima, M.; Somiya, M.; Yoshimoto, N.; Niimi, T.; Kuroda, S.I. Nano-visualization of orientedimmobilized IgGs on immunosensors by high-speed atomic force microscopy. Sci. Rep. 2012, 2, 790.
148. Tsutsui, Y.; Tomizawa, K.; Nagita, M.; Michiue, H.; Nishiki, T.-I.; Ohmori, I.; Seno, M.; Matsui, H. Development of bionanocapsules targeting brain tumors. J. Control. Release 2007, 122, 159-164.
149. Mazor, Y.; Barnea, I.; Keydar, I.; Benhar, I. Antibody internalization studied using a novel IgG binding toxin fusion. J. Immunol. Methods 2007, 321, 41-59.
150. Mazor, Y.; Noy, R.; Wels, W.S.; Benhar, I. chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2- expressing tumor xenografts. Cancer Lett. 2007, 257, 124-135.
151. Shapira, S.; Shapira, A.; Starr, A.; Kazanov, D.; Kraus, S.; Benhar, I.; Arber, N. An immunoconjugate of anti-CD24 and Pseudomonas exotoxin selectively kills human colorectal tumors in mice. Gastroenterology 2011, 140, 935-946.
152. Barnea, I.; Ben-Yosef, R.; Karaush, V.; Benhar, I.; Vexler, A. Targeting EGFR-positive cancer cells with cetuximab-ZZ-PE38: Results of in vitro and in vivo studies. Head Neck 2013, 35, 1171-1177.
153. Sakamoto, T.; Sawamoto, S.; Tanaka, T.; Fukuda, H.; Kondo, A. Enzyme-mediated site-specific antibody-protein modification using a ZZ domain as a linker. Bioconjug. Chem. 2010, 21, 2227-2233.
154. Konrad, A.; Karlstrom, A.E.; Hober, S. Covalent immunoglobulin labeling through a photoactivable synthetic Z domain. Bioconjug. Chem. 2011, 22, 2395-2403.
155. Yu, F.; Järver, P.; Nygren, P.-Å.Å. Tailor-making a protein a-derived domain for efficient site-specific photocoupling to Fc of mouse IgG1. PLoS One 2013, 8, e56597:11.
156. Perols, A.; Karlström, A.E. Site-specific photoconjugation of antibodies using chemically synthesized IgG-binding domains. Bioconjug. Chem. 2014, 25, 481-488.
157. Hui, J.Z.; Tsourkas, A. Optimization of photoactive protein Z for fast and efficient site-specific conjugation of native IgG. Bioconjug. Chem. 2014, 25, 1709-1719.
158. Jung, Y.; Lee, J.M.; Kim, J.W.; Yoon, J.; Cho, H.; Chung, B.H. Photoactivable antibody binding protein: site-selective and covalent coupling of antibody. Anal. Chem. 2009, 81, 936-942.
159. Rajagopalan, K.; Pavlinkova, G.; Levy, S.; Pokkuluri, P.R.; Schiffer, M.; Haley, B.E.; Kohler, H. Novel unconventional binding site in the variable region of immunoglobulins. Proc. Natl. Acad. Sci. USA 1996, 93, 6019-6024.
160. Pavlinkova, G.; Rajagopalan, K.; Muller, S.; Chavan, A.; Sievert, G.; Lou, D.; O'Toole, C.; Haley, B.; Kohler, H. Site-specific photobiotinylation of immunoglobulins, fragments and light chain dimers. J. Immunol. Methods 1997, 201, 77-88.
161. Pavlinkova, G.; Lou, D.; Kohler, H. Site-specific photobiotinylation of antibodies, light chains, and immunoglobulin fragments. Methods 2000, 22, 44-48.
162. Alves, N.J.; Champion, M.M.; Stefanick, J.F.; Handlogten, M.W.; Moustakas, D.T.; Shi, Y.; Shaw, B.F.; Navari, R.M.; Kiziltepe, T.; Bilgicer, B. Selective photocrosslinking of functional ligands to antibodies via the conserved nucleotide binding site. Biomaterials 2013, 34, 5700-5710.
163. Alves, N.J.; Mustafaoglu, N.; Bilgicer, B. Conjugation of a reactive thiol at the nucleotide binding site for site-specific antibody functionalization. Bioconjug. Chem. 2014, 25, 1198-1202.
164. Wagner, J.; Lerner, R.; Barbas, C. Efficient aldolase catalytic antibodies that use the enamine mechanism of natural enzymes. Science 1995, 270, 1797-1800.
165. Barbas, C.; Heine, A.; Zhong, G.; Hoffmann, T.; Gramatikova, S.; Björnestedt, R.; List, B.; Anderson, J.; Stura, E.; Wilson, I.; et al. Immune versus natural selection: antibody aldolases with enzymic rates but broader scope. Science 1997, 278, 2085-2092.
166. Tanaka, F.; Almer, H.; Lerner, R.A.; Barbas, C.F. Catalytic single-chain antibodies possessing ß-lactamase activity selected from a phage displayed combinatorial library using a mechanismbased inhibitor. Tetrahedron Lett. 1999, 40, 8063-8066.
167. Tanaka, F.; Barbas, C. Reactive immunization: A unique approach to catalytic antibodies. J. Immunol. Methods 2002, 269, 67-79.
168. Sinha, S.C.; Das, S.; Li, L.S.; Lerner, R.A.; Barbas, C.F., 3rd. Preparation of integrin alpha(v)beta3-targeting Ab 38C2 constructs. Nat. Protoc. 2007, 2, 449-456.
169. Bhat, A.; Laurent, O.; Lappe, R. CovX-Bodies. In Fusion Protein Technologies for Biopharmaceuticals; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2013; pp. 571-582.
170. Rader, C. Chemically programmed antibodies. Trends Biotechnol. 2014, 32, 186-197.
171. Rader, C.; Sinha, S.; Popkov, M.; Lerner, R.; Barbas, C. Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst. Proc. Natl. Acad. Sci. USA 2003, 100, 5396-5400.
172. Doppalapudi, V.; Tryder, N.; Li, L.; Aja, T.; Griffith, D.; Liao, F.-F.; Roxas, G.; Ramprasad, M.; Bradshaw, C.; Barbas, C. Chemically programmed antibodies: Endothelin receptor targeting CovX-Bodies. Bioorg. Med. Chem. Lett. 2007, 17, 501-506.
173. Coronella, J.; Li, L.; Johnson, K.; Pirie-Shepherd, S.; Roxas, G.; Levin, N. Selective activity against proliferating tumor endothelial cells by CVX-22, a thrombospondin-1 mimetic CovX-Body. Anticancer Res. 2009, 29, 2243-2252.
174. Doppalapudi, V.; Huang, J.; Liu, D.; Jin, P.; Liu, B.; Li, L.; Desharnais, J.; Hagen, C.; Levin, N.; Shields, M.; et al. Chemical generation of bispecific antibodies. Proc. Natl. Acad. Sci. USA 2010, 107, 22611-22616.
175. Li, L.; Leedom, T.A.; Do, J.; Huang, H.; Lai, J.; Johnson, K.; Osothprarop, T.F.; Rizzo, J.D.; Doppalapudi, V.R.; Bradshaw, C.W.; et al. Antitumor efficacy of a thrombospondin 1 mimetic CovX-body. Transl. Oncol. 2011, 4, 249-257.
176. Goswami, R.K.; Bajjuri, K.M.; Forsyth, J.S.; Das, S.; Hassenpflug, W.; Huang, Z.Z.; Lerner, R.A.; Felding-Habermann, B.; Sinha, S.C. Chemically programmed antibodies targeting multiple alpha(v) integrins and their effects on tumor-related functions in vitro. Bioconjug. Chem. 2011, 22, 1535-1544.
177. Goswami, R.K.; Liu, Y.; Liu, C.; Lerner, R.A.; Sinha, S.C. Synthesis and evaluation of the aldolase antibody-derived chemical-antibodies targeting alpha5beta1 integrin. Mol. Pharm. 2013, 10, 538-543.
178. Liu, Y.; Goswami, R.K.; Liu, C.; Sinha, S.C. Chemically programmed bispecific antibody targeting legumain protease and alphavbeta3 integrin mediates strong antitumor effects. Mol. Pharm. 2015, 12, 2544-2550.
179. Sato, S.; Inokuma, T.; Otsubo, N.; Burton, D.R.; Barbas, C.F., 3rd. Chemically programmed antibodies as HIV-1 attachment inhibitors. ACS Med. Chem. Lett. 2013, 4, 460-465.
180. Hayakawa, M.; Toda, N.; Carrillo, N.; Thornburg, N.J.; Crowe, J.E., Jr.; Barbas, C.F., 3rd. A chemically programmed antibody is a long-lasting and potent inhibitor of influenza neuraminidase. ChemBioChem 2012, 13, 2191-2195.
181. Roberts, L.; Brady, K.; Brown, A.; Davey, D.; Feng, L.; Huang, H.; Liu, D.; Malet, L.; McMurray, G.; Phelan, A.; et al. Kappa agonist CovX-Bodies. Bioorg. Med. Chem. Lett. 2012, 22, 4173-4178.
182. Palanki, M.S.S.; Bhat, A.; Bolanos, B.; Brunel, F.; Del Rosario, J.; Dettling, D.; Horn, M.; Lappe, R.; Preston, R.; Sievers, A.; et al. Development of a long acting human growth hormone analog suitable for once a week dosing. Bioorg. Med. Chem. Lett. 2013, 23, 402-406.